• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CRVS

CRVS

Corvus Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD11.60

-0.09 (-0.77%)

Rating:C

Company Profile

CEO

Richard A. Miller

IPO Date

2016-03-23

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$11.76

Prev. Close

$11.69

Day Low

$11.36

Day High

$11.80

52W Low

$3.55

52W High

$26.95

Market Cap

$0.98B

Volume

1.60M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

22.2%

Avg Negative

11.9%

Avg Neutral

65.8%

News Feed

4 Penny Stocks Insiders Are Buying

Benzinga·8/24/2021·↑ positive

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

GlobeNewsWire·8/16/2021·↑ positive

Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)

Zacks Investment Research·8/5/2021·↓ negative

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

GlobeNewsWire·8/2/2021·↓ negative

Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

Zacks Investment Research·7/20/2021·↑ positive

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

GlobeNewsWire·7/15/2021·↑ positive

Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/25/2021·↑ positive

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

GlobeNewsWire·5/5/2021·↑ positive

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

GlobeNewsWire·4/29/2021·↑ positive

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewsWire·3/25/2021·↑ positive